[go: up one dir, main page]

PE20110565A1 - Metodo de identificacion de factores de riesgo de la enfermedad - Google Patents

Metodo de identificacion de factores de riesgo de la enfermedad

Info

Publication number
PE20110565A1
PE20110565A1 PE2011000157A PE2011000157A PE20110565A1 PE 20110565 A1 PE20110565 A1 PE 20110565A1 PE 2011000157 A PE2011000157 A PE 2011000157A PE 2011000157 A PE2011000157 A PE 2011000157A PE 20110565 A1 PE20110565 A1 PE 20110565A1
Authority
PE
Peru
Prior art keywords
disease
affected
subjects
genetic
interest
Prior art date
Application number
PE2011000157A
Other languages
English (en)
Inventor
Allen D Roses
Original Assignee
Zinfandel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41669605&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20110565(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zinfandel Pharmaceuticals Inc filed Critical Zinfandel Pharmaceuticals Inc
Publication of PE20110565A1 publication Critical patent/PE20110565A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)

Abstract

SE REFIERE A UN PROCEDIMIENTO PARA IDENTIFICAR UNA VARIANTE GENETICA QUE ESTA ASOCIADA CON EL DESARROLLO DE UNA ENFERMEDAD SELECCIONADA ENTRE DIABETES MLLITUS TIPO II, PARKINSON, ALZHEIMER, ENTRE OTROS, QUE COMPRENDE: A) DETERMINAR LAS MUESTRAS BIOLOGICAS QUE CONTIENEN EL ADN LAS SECUENCIAS DE NUCLEOTIDOS PORTADAS POR UNA PLURALIDAD DE SUJETOS EN UN LUGAR GENETICO DE INTERES, DONDE DICHOS SUJETOS INCLUYEN LOS AFECTADOS COMO LOS NO AFECTADOS POR UNA ENFERMEDAD DE INTERES; B) REALIZAR EL ANALISIS DE ALINEACION DE SECUENCIAS MULTIPLES PARA IDENTIFICAR LAS VARIANTES GENETICAS; C) MAPEAR DICHAS VARIANTES GENETICAS PARA CONSTRUIR UN ARBOL FILOGENETICO DE DICHOS SUJETOS; D) EXAMINAR LAS VARIANTES GENETICAS REPRESENTADAS COMO RAMAS EN DICHO ARBOL Y DETERMINAR LA PROPORCION DE SUJETOS AFECTADOS Y NO AFECTADOS; E) IDENTIFICAR UNA VARIANTE GENETICA ASOCIADA CON EL DESARROLLO DE DICHO PADECIMIENTO DE INTERES
PE2011000157A 2008-08-12 2009-08-11 Metodo de identificacion de factores de riesgo de la enfermedad PE20110565A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8820308P 2008-08-12 2008-08-12
US18667309P 2009-06-12 2009-06-12
US22464709P 2009-07-10 2009-07-10

Publications (1)

Publication Number Publication Date
PE20110565A1 true PE20110565A1 (es) 2011-09-02

Family

ID=41669605

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2015002280A PE20151924A1 (es) 2008-08-12 2009-08-11 Metodo de identificacion de factores de riesgo de la enfermedad
PE2015000030A PE20150362A1 (es) 2008-08-12 2009-08-11 Metodo de identificacion de factores de riesgo de la enfermedad
PE2011000157A PE20110565A1 (es) 2008-08-12 2009-08-11 Metodo de identificacion de factores de riesgo de la enfermedad

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PE2015002280A PE20151924A1 (es) 2008-08-12 2009-08-11 Metodo de identificacion de factores de riesgo de la enfermedad
PE2015000030A PE20150362A1 (es) 2008-08-12 2009-08-11 Metodo de identificacion de factores de riesgo de la enfermedad

Country Status (31)

Country Link
US (4) US8815508B2 (es)
EP (2) EP2789695B1 (es)
JP (4) JP5833922B2 (es)
KR (3) KR101729340B1 (es)
CN (3) CN102177436B (es)
AU (3) AU2009282114B2 (es)
BR (1) BRPI0917948A2 (es)
CA (1) CA2735578C (es)
CL (1) CL2011000298A1 (es)
CO (1) CO6351823A2 (es)
CY (1) CY1115412T1 (es)
DK (1) DK2324126T3 (es)
DO (1) DOP2011000052A (es)
EA (1) EA021399B1 (es)
ES (1) ES2463766T3 (es)
GE (1) GEP20146107B (es)
HR (1) HRP20140709T1 (es)
IL (2) IL211140A (es)
MA (1) MA32619B1 (es)
ME (1) ME01898B (es)
MX (1) MX2011001671A (es)
NZ (3) NZ619895A (es)
PE (3) PE20151924A1 (es)
PL (1) PL2324126T3 (es)
PT (1) PT2324126E (es)
RS (1) RS53383B (es)
SG (1) SG193793A1 (es)
SI (1) SI2324126T1 (es)
SM (1) SMT201400088B (es)
WO (1) WO2010019550A2 (es)
ZA (1) ZA201101095B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
MX2011001671A (es) * 2008-08-12 2011-06-17 Zinfandel Pharmaceuticals Inc Metodo de identificacion de factores de riesgo de la enfermedad.
CA2797645C (en) 2010-05-25 2020-09-22 The Regents Of The University Of California Bambam: parallel comparative analysis of high-throughput sequencing data
US9646134B2 (en) * 2010-05-25 2017-05-09 The Regents Of The University Of California Bambam: parallel comparative analysis of high-throughput sequencing data
JP2014505055A (ja) 2011-01-10 2014-02-27 ジンファンデル ファーマシューティカルズ インコーポレイテッド アルツハイマー病を治療するための方法及び製剤
AU2013204020B2 (en) * 2011-01-10 2016-03-31 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
CA2824024A1 (en) * 2011-01-10 2012-07-19 Zinfandel Pharmaceuticals, Inc. Tomm40 variants as genetic markers for alzheimer's disease
US20120231457A1 (en) * 2011-03-10 2012-09-13 Nikolaos Tezapsidis Compositions and methods for assessing a genetic risk of developing late-onset alzheimer's disease (load)
US8718950B2 (en) 2011-07-08 2014-05-06 The Medical College Of Wisconsin, Inc. Methods and apparatus for identification of disease associated mutations
US20130080182A1 (en) * 2011-09-26 2013-03-28 Athleticode Inc. Methods For Using DNA Testing To Screen For Genotypes Relevant To Athleticism, Health And Risk Of Injury
WO2013106084A1 (en) * 2012-01-09 2013-07-18 Takeda Pharmaceutical Company Limited Methods and drug products for treating alzheimer's disease
GB201209689D0 (en) * 2012-05-31 2012-07-18 Imp Innovations Ltd Methods
EP2962270A4 (en) 2013-03-01 2016-08-24 Actx Inc CLOUD-ARTIGER MEDICAL INFORMATION SERVICE
JPWO2015174544A1 (ja) * 2014-05-16 2017-04-20 国立研究開発法人国立精神・神経医療研究センター 精神疾患判定マーカー
CA2992616C (en) 2015-07-23 2023-01-03 Asuragen, Inc. Methods, compositions, kits, and uses for analysis of nucleic acids comprising repeating a/t-rich segments
CN117286238A (zh) * 2016-05-20 2023-12-26 西达-赛奈医疗中心 基于基因的炎性肠病诊断
CN105969885A (zh) * 2016-06-24 2016-09-28 江苏雄鸣医药科技有限公司 一种阿尔兹海默症的基因诊断试剂盒
WO2018132755A1 (en) * 2017-01-12 2018-07-19 Duke University Compositions and methods for disrupting the molecular mechanisms associated with mitochondrial dysfunction and neurodegenerative disease
CA3057289A1 (en) 2017-03-21 2018-09-27 The Jackson Laboratory A genetically modified mouse expressing human apoe4 and mouse trem2 p.r47h and methods of use thereof
WO2019023247A1 (en) 2017-07-25 2019-01-31 Immutics, Inc. TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND
EP3662290A4 (en) * 2017-07-31 2021-03-31 Quest Diagnostics Investments LLC Apolipoprotein e isotype detection by mass spectrometry
BR112020007367A2 (pt) * 2017-10-31 2020-09-29 Ge Healthcare Limited sistemas médicos para predição de uma patologia de doença e para predição da evolução clínica em um indivíduo com estado cognitivo incerto, métodos para predição da patologia de uma doença e para predição da evolução clínica em um indivíduo com estado cognitivo incerto, sistema médico para identificação de indivíduos que estão em risco de desenvolver a doença de alzheimer, métodos para identificação de indivíduos que estão em risco de desenvolver a doença de alzheimer, para determinação de um prognóstico para um paciente com doença de alzheimer e de tratamento de um paciente para doença de alzheimer, uso de dados médicos de um ou mais indivíduos com evoluções desconhecidas para doença de alzheimer, e, sistemas médicos para classificação de indivíduos como portadores de comprometimento cognitivo leve ou doença de alzheimer, para classificação de indivíduos como portadores de doença de alzheimer ou de alguma outra forma de demência e para identificação de indicações adicionais para um fármaco
EP3747015A4 (en) * 2018-01-31 2021-11-03 Curelator Inc. EARLY FEEDBACK OF DISEASE FACTORS TO IMPROVE A PATIENT'S QUALITY OF LIFE, ENGAGEMENT AND PERSISTENCE
KR102303638B1 (ko) * 2018-04-13 2021-09-23 사회복지법인 삼성생명공익재단 알츠하이머성 치매가 발병될 가능성 평가방법
WO2019215085A1 (en) 2018-05-07 2019-11-14 Biotx.Ai Gmbh Method for predicting the risk of late-onset alzheimer's diseases
CA3100897A1 (en) 2018-05-18 2019-11-21 Anavex Life Sciences Corp. Optimized sigma-1 agonist method of responder selection and treatment
EP3626835A1 (en) * 2018-09-18 2020-03-25 Sistemas Genómicos, S.L. Method for genotypically identifying both alleles of at least one locus of a subject's hla gene
KR102127903B1 (ko) * 2019-01-29 2020-06-29 연세대학교 산학협력단 염증성 호흡기 질환의 진단용 바이오마커
CN116063505B (zh) 2019-01-30 2024-05-03 真和制药有限公司 抗gal3抗体及其用途
WO2020237314A1 (en) * 2019-05-30 2020-12-03 The University Of Newcastle A method of treatment or prophylaxis
CN111593107A (zh) * 2020-01-15 2020-08-28 丁玎 阿尔兹海默症易感位点rs10119与rs71352238的检测方法及试剂盒
CN111187825A (zh) * 2020-01-15 2020-05-22 丁玎 阿尔兹海默症的tomm40基因及apoe基因的易感位点的检测方法及试剂盒
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
KR102535235B1 (ko) * 2020-11-25 2023-05-26 서울대학교산학협력단 알츠하이머병 발병 위험도 예측을 위한 단일염기다형성 마커 및 이의 용도
RU2757522C1 (ru) * 2021-06-02 2021-10-18 Федеральное Государственное Бюджетное Учреждение "Национальный Медицинский Исследовательский Центр Эндокринологии" Министерства Здравоохранения Российской Федерации (Фгбу "Нмиц Эндокринологии" Минздрава России) СПОСОБ ПРОГНОЗИРОВАНИЯ РАЗВИТИЯ ХРОНИЧЕСКОЙ БОЛЕЗНИ ПОЧЕК У ПАЦИЕНТОВ С САХАРНЫМ ДИАБЕТОМ 1 и 2 ТИПА (варианты)
US12367979B2 (en) 2021-07-21 2025-07-22 The Catholic University Of Korea Industry-Academic Cooperation Foundation Method and apparatus for determining dementia risk factors using deep learning
KR102770667B1 (ko) * 2022-04-22 2025-02-21 사회복지법인 삼성생명공익재단 유럽-동아시아인 데이터 기반 알츠하이머병 치매의 발병 위험군 또는 조기 증상 발현 위험군, 기억상실형 경도인지장애의 발병 위험군 및/또는 아밀로이드β 침착에 대한 PET 양성 위험군을 예측하기 위한 정보를 제공하는 방법

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US663780A (en) * 1898-09-09 1900-12-11 Wheeler & Wilson Mfg Co Trimming attachment for sewing-machines.
US4302204A (en) 1979-07-02 1981-11-24 The Board Of Trustees Of Leland Stanford Junior University Transfer and detection of nucleic acids
US4358535A (en) 1980-12-08 1982-11-09 Board Of Regents Of The University Of Washington Specific DNA probes in diagnostic microbiology
FI63596C (fi) 1981-10-16 1983-07-11 Orion Yhtymae Oy Mikrobdiagnostiskt foerfarande som grundar sig pao skiktshybridisering av nukleinsyror och vid foerfarandet anvaenda kombinationer av reagenser
US4994373A (en) 1983-01-27 1991-02-19 Enzo Biochem, Inc. Method and structures employing chemically-labelled polynucleotide probes
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
US6060237A (en) 1985-02-26 2000-05-09 Biostar, Inc. Devices and methods for optical detection of nucleic acid hybridization
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5112460A (en) * 1986-10-21 1992-05-12 Northeastern University High performance microcapillary gel electrophoresis
DE3856378T2 (de) * 1987-09-04 2000-05-11 Beecham Group P.L.C., Brentford Substituierte Thiazolidindionderivate
US5595883A (en) 1990-06-01 1997-01-21 E. R. Squibb & Sons, Inc. Method of diagnosing alzheimer's disease by measuring acetylcholinesterase activity in ocular fluid
US5171750A (en) 1991-09-26 1992-12-15 The United States Of America As Represented By The Department Of Health And Human Services Substituted phenserines as specific inhibitors of acetylcholinesterase
TW263504B (es) 1991-10-03 1995-11-21 Pfizer
US5326770A (en) * 1992-07-17 1994-07-05 The Du Pont Merck Pharmaceutical Company Monoamine oxidase-B (MAO-B) inhibitory 5-substituted 2,4-thiazolidinediones useful in treating memory disorders of mammals
ZA936492B (en) * 1992-09-10 1995-03-02 Lilly Co Eli Compounds useful as hypoglycemic agents and for treating Alzheimer's disease.
DE625212T1 (de) * 1992-10-13 2000-11-02 Duke University, Durham Verfahren zum entdecken von krankheit von alzheimer.
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
ES2100129B1 (es) 1995-10-11 1998-02-16 Medichem Sa Nuevos compuestos aminopiridinicos policiclicos inhibidores de acetilcolinesterasa, procedimiento para su preparacion y su utilizacion.
JPH09176162A (ja) 1995-12-22 1997-07-08 Toubishi Yakuhin Kogyo Kk チアゾリジンジオン誘導体及びその製造法並びにそれを含む医薬組成物
US6128587A (en) 1997-01-14 2000-10-03 The Regents Of The University Of California Method and apparatus using Bayesian subfamily identification for sequence analysis
US5904824A (en) * 1997-03-07 1999-05-18 Beckman Instruments, Inc. Microfluidic electrophoresis device
CA2323889A1 (en) * 1997-03-12 1998-09-17 Robert W. Esmond A method for treating or preventing alzheimer's disease
EP0869122B1 (en) * 1997-03-31 2002-12-04 Korea Research Institute Of Chemical Technology Quinolinic sulfide derivatives acting as NMDA receptor antagonists and process for preparation thereof
ES2259459T3 (es) * 1997-11-19 2006-10-01 Takeda Pharmaceutical Company Limited Nuevos inhibidores de apoptosis.
US6964868B1 (en) 1998-01-28 2005-11-15 Nuvelo, Inc. Human genes and gene expression products II
US7122373B1 (en) 1998-05-14 2006-10-17 Nuvelo, Inc. Human genes and gene expression products V
US20040058873A1 (en) * 1998-03-12 2004-03-25 Esmond Robert W. Method for treating or preventing Alzheimer's disease
DE69929787T2 (de) 1998-06-16 2006-11-09 Poirier, Judes Verfahren zur behandlung von neurologischen erkrankungen mit hilfe der bestimmung des bche genotyps
EP1117840A1 (en) 1998-10-01 2001-07-25 Variagenics, Inc. Methods for treating or identifying a subject at risk for a neurological disease by determining the presence of a variant gpiiia and/or variant gpiib allele
ES2229781T3 (es) 1998-11-10 2005-04-16 Genset Metodos programas y aparatos para identificar regiones genomicas que albergan un gen asociado con un rasgo detectable.
US6191154B1 (en) * 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
CN1078616C (zh) * 1998-12-16 2002-01-30 中国科学院上海生命科学研究中心 一种检测样品中是否存在老年痴呆病基因的方法和试剂盒
JP2000273040A (ja) * 1999-01-19 2000-10-03 Sankyo Co Ltd トログリタゾンを含有するアポトーシス抑制剤
US6401043B1 (en) * 1999-04-26 2002-06-04 Variagenics, Inc. Variance scanning method for identifying gene sequence variances
AU776162B2 (en) 1999-04-29 2004-08-26 City Of Hope Pentoxifylline, pioglitazone and metformin are inhibitors of formation of advanced glycation endproducts (AGE's)
US6573049B1 (en) 1999-07-26 2003-06-03 Nuvelo, Inc. Genotyping of the paraoxonase 1 gene for prognosing, diagnosing, and treating a disease
DE19936719A1 (de) 1999-08-06 2001-02-15 Gruenenthal Gmbh Substituierte 1,5-Dihydropyrrol-2-on-Derivate
US6559188B1 (en) 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
AR030920A1 (es) 1999-11-16 2003-09-03 Smithkline Beecham Plc Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6532467B1 (en) 2000-04-10 2003-03-11 Sas Institute Inc. Method for selecting node variables in a binary decision tree structure
US6432985B2 (en) * 2000-04-25 2002-08-13 Hoffmann-La Roche Inc. Neuroprotective substituted piperidine compounds with activity as NMDA NR2B subtype selective antagonists
JP2004531459A (ja) 2000-10-11 2004-10-14 エスペリオン セラピューティクス，インコーポレイテッド コレステロールマネージメント用スルホキシドおよびビススルホキシド化合物ならびに組成物および関連する使用
CA2425311C (en) 2000-10-11 2011-06-14 Esperion Therapeutics, Inc. Ketone compounds and compositions for cholesterol management and related uses
US20040122091A1 (en) * 2000-10-11 2004-06-24 Esperion Therapeutics, Inc. Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
BR0114619A (pt) * 2000-10-11 2005-12-13 Esperion Therapeutics Inc Composto, composição farmacêutica, métodos para tratar ou prevenir uma doença cardiovascular, uma dislipidemia, uma dislipoproteinemia, um distúrbio do metabolismo da glicose, trombótico e associado com o receptor ativado do proliferador de peroxissoma, a doença de alzheimer, a sìndrome x ou sìndrome metabólica, a septicemia, a obesidade, pancreatite, a hipertensão, doença renal, câncer, a inflamação e a impotência, em um paciente e para reduzir o teor de gordura da carne em animal de criação e de colesterol de ovos de aves domésticas
US7304093B2 (en) * 2000-10-11 2007-12-04 Esperion Therapeutics, Inc. Ketone compounds and compositions for cholesterol management and related uses
KR100865142B1 (ko) 2000-11-24 2008-10-24 바스큘라 바이오제닉스 리미티드 죽상 경화증의 예방 및 치료를 위해 정의된 산화 인지질을사용하는 방법 및 이를 함유하는 조성물
US6838452B2 (en) 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6495335B2 (en) 2000-12-07 2002-12-17 Mario Chojkier Compositions and methods for diagnosing alzheimer's disease
DE10132725A1 (de) 2001-07-05 2006-08-03 Grünenthal GmbH Substituierte γ-Lactonverbindungen
US6680299B2 (en) 2001-07-27 2004-01-20 Enanta Pharmaceuticals, Inc. 4'-substituted leucomycins
US20040204502A1 (en) * 2001-10-11 2004-10-14 Dasseux Jean-Louis Henri Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
US20050020694A1 (en) 2001-10-11 2005-01-27 Dasseux Jean-Louis Henri Sulfide and disulfide compounds and compositions for cholesterol management and related uses
US6828462B2 (en) 2001-11-07 2004-12-07 Merz Pharma Gmbh & Co. Kgaa Unsaturated 1-amino-alkylcyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists
US7132244B2 (en) 2001-11-21 2006-11-07 Syn X Pharma, Inc. Betaine/GABA transport protein biopolymer marker indicative of insulin resistance
US7135297B2 (en) 2001-11-23 2006-11-14 Nanogen Inc. Protein biopolymer markers indicative of insulin resistance
US7052849B2 (en) 2001-11-23 2006-05-30 Syn X Pharma, Inc. Protein biopolymer markers predictive of insulin resistance
US20030220374A1 (en) * 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
AU2003246254A1 (en) 2002-07-05 2004-01-23 Shionogi And Co., Ltd. NOVEL Nogo RECEPTOR-LIKE POLYPEPTIDE AND DNA THEREOF
US20040265849A1 (en) * 2002-11-22 2004-12-30 Applera Corporation Genetic polymorphisms associated with Alzheimer's disease, methods of detection and uses thereof
CN1753662A (zh) * 2002-12-24 2006-03-29 神经化学（国际）有限公司 用于治疗β－淀粉状蛋白相关疾病的治疗制剂
JP2006519440A (ja) * 2003-02-14 2006-08-24 インタージェネティックス インコーポレイテッド 疾患の増大リスクの統計学的同定法
US7141669B2 (en) 2003-04-23 2006-11-28 Pfizer Inc. Cannabiniod receptor ligands and uses thereof
US20050004179A1 (en) * 2003-05-22 2005-01-06 Pedersen Ward A. Methods and materials for treating, detecting, and reducing the risk of developing Alzheimer's Disease
WO2005003766A2 (en) 2003-06-13 2005-01-13 Whitehead Institute For Biomedical Research Methods of regulating metabolism and mitochondrial function
US8084645B2 (en) 2003-09-19 2011-12-27 Chugai Seiyaku Kabushiki Kaisha 4-phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (MEK) inhibitors
JP2007526764A (ja) 2004-01-22 2007-09-20 ジェネッサンス ファーマシューティカルズ，インコーポレイティド アルツハイマー病の発症年齢に関連するａｐｏｅ遺伝子マーカー
TW200538738A (en) 2004-02-20 2005-12-01 Univ California Molecular flux rates through critical pathways measured by stable isotope labeling in vivo, as biomarkers of drug action and disease activity
WO2006054297A2 (en) 2004-11-17 2006-05-26 Compugen Ltd. Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
EP1859056A2 (en) * 2005-01-31 2007-11-28 Perlegen Sciences, Inc. Genetic basis of alzheimer's disease and diagnosis and treatment thereof
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EA200800880A1 (ru) 2005-09-22 2009-02-27 Смитклайн Бичам (Корк) Лимитед Комбинация росиглитазона и донепезила, предназначенная для улучшения когнитивной функции
WO2007044522A1 (en) 2005-10-05 2007-04-19 Auburn University P62 as a risk determinant for metabolic syndrome
CN101454005B (zh) 2006-03-16 2013-01-02 新陈代谢解决方案开发公司 用于治疗代谢性炎症介导的疾病的噻唑烷二酮类似物
US20080045582A1 (en) 2006-05-15 2008-02-21 Issam Zineh ENA-78 Gene Polymorphisms and Protein Concentrations as Diagnostic and Prognostic Tools
CA2653974A1 (en) 2006-05-30 2008-02-14 Mayo Foundation For Medical Education And Research Detecting and treating dementia
US7651840B2 (en) * 2006-07-14 2010-01-26 Celera Corporation Genetic polymorphisms associated with Alzheimer's disease, methods of detection and uses thereof
US20080103165A1 (en) 2006-09-19 2008-05-01 Braincells, Inc. Ppar mediated modulation of neurogenesis
US20090042849A1 (en) 2006-12-06 2009-02-12 Yochai Birnbaum Phosphorylation of 5-lipoxygenase at ser523 and uses thereof
US7794937B2 (en) 2006-12-22 2010-09-14 Quest Diagnostics Investments Incorporated Cystic fibrosis transmembrane conductance regulator gene mutations
GB0702537D0 (en) 2007-02-12 2007-03-21 Leuven K U Res & Dev Treatment for excessive adiposity
US20080286876A1 (en) 2007-05-14 2008-11-20 Chissoe Stephanie GENES ASSOCIATED WITH ALZHEIMER'S DISEASE - Hltdip
US8652508B2 (en) 2007-05-25 2014-02-18 Children's Medical Center Corporation Dietary formulations and methods for treatment of inflammation and other disorders
TW200914006A (en) 2007-07-12 2009-04-01 Takeda Pharmaceutical Coated preparation
US8846315B2 (en) * 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
MX2011001671A (es) * 2008-08-12 2011-06-17 Zinfandel Pharmaceuticals Inc Metodo de identificacion de factores de riesgo de la enfermedad.
US20100136584A1 (en) 2008-09-22 2010-06-03 Icb International, Inc. Methods for using antibodies and analogs thereof
US20100092470A1 (en) 2008-09-22 2010-04-15 Icb International, Inc. Antibodies, analogs and uses thereof
CN102308004A (zh) 2008-10-30 2012-01-04 卡里斯生命科学卢森堡控股有限责任公司 评价rna图案的方法
GB2463401B (en) 2008-11-12 2014-01-29 Caris Life Sciences Luxembourg Holdings S A R L Characterizing prostate disorders by analysis of microvesicles
CN102245581A (zh) 2008-12-12 2011-11-16 普克塞尔公司 用于治疗与ampk活性有关的疾病的四氢三嗪化合物
KR101682489B1 (ko) 2009-02-02 2016-12-05 라일라 뉴트라슈티칼스 대사성 증후군의 조절을 위한 스파란터스 인디커스 및 가르시니아 망고스타나 유래의 조성물
US8865648B2 (en) 2009-04-23 2014-10-21 Siemens Healthcare Diagnostics Inc. Monomeric and dimeric forms of adiponectin receptor fragments and methods of use
AU2010202926B2 (en) 2009-09-11 2016-07-14 Electrophoretics Limited Markers and methods relating to the assessment of Alzheimer's disease
US20110195488A1 (en) 2010-02-10 2011-08-11 Selinfreund Richard H Devices for collection and stabilization of biomarkers in liquid samples
KR20130056855A (ko) 2010-03-01 2013-05-30 카리스 라이프 사이언스 룩셈부르크 홀딩스 치료진단용 생물학적 지표들
KR20130043104A (ko) 2010-04-06 2013-04-29 카리스 라이프 사이언스 룩셈부르크 홀딩스 질병용 순환 생물학적 지표들
JP2014505055A (ja) * 2011-01-10 2014-02-27 ジンファンデル ファーマシューティカルズ インコーポレイテッド アルツハイマー病を治療するための方法及び製剤

Also Published As

Publication number Publication date
AU2009282114A2 (en) 2011-04-28
RS53383B (sr) 2014-10-31
US10865449B2 (en) 2020-12-15
AU2009282114A1 (en) 2010-02-18
IL211140A0 (en) 2011-04-28
IL239277A0 (en) 2015-07-30
JP2016047058A (ja) 2016-04-07
KR20160127181A (ko) 2016-11-02
JP2018075005A (ja) 2018-05-17
EA021399B1 (ru) 2015-06-30
KR20110063453A (ko) 2011-06-10
US8815508B2 (en) 2014-08-26
NZ619895A (en) 2015-12-24
KR20180053432A (ko) 2018-05-21
MX2011001671A (es) 2011-06-17
CO6351823A2 (es) 2011-12-20
WO2010019550A3 (en) 2010-04-22
ZA201101095B (en) 2012-07-25
SG193793A1 (en) 2013-10-30
CN104611421B (zh) 2018-08-07
CN104611421A (zh) 2015-05-13
EP2324126A4 (en) 2012-05-30
US20210095345A1 (en) 2021-04-01
AU2016204678A1 (en) 2016-07-21
EA201170332A1 (ru) 2011-10-31
EP2789695A1 (en) 2014-10-15
MA32619B1 (fr) 2011-09-01
JP2019076095A (ja) 2019-05-23
CA2735578C (en) 2018-10-23
EP2324126A2 (en) 2011-05-25
JP2012500004A (ja) 2012-01-05
CN104805198B (zh) 2019-04-26
AU2016204678B2 (en) 2018-04-19
DOP2011000052A (es) 2011-04-15
SI2324126T1 (sl) 2014-07-31
CN102177436B (zh) 2015-05-13
KR101729340B1 (ko) 2017-04-24
CN104805198A (zh) 2015-07-29
GEP20146107B (en) 2014-06-10
DK2324126T3 (da) 2014-06-16
WO2010019550A2 (en) 2010-02-18
HRP20140709T1 (hr) 2014-09-26
NZ591107A (en) 2012-08-31
PE20150362A1 (es) 2015-03-20
JP6815372B2 (ja) 2021-01-20
BRPI0917948A2 (pt) 2017-06-20
SMT201400088B (it) 2014-09-08
EP2789695B1 (en) 2019-10-30
JP5833922B2 (ja) 2015-12-16
ES2463766T3 (es) 2014-05-29
HK1153511A1 (en) 2012-03-30
WO2010019550A4 (en) 2011-01-13
NZ710443A (en) 2019-03-29
PL2324126T3 (pl) 2014-09-30
CN102177436A (zh) 2011-09-07
US20180363060A1 (en) 2018-12-20
CY1115412T1 (el) 2017-01-04
IL211140A (en) 2015-06-30
US20110189165A1 (en) 2011-08-04
CL2011000298A1 (es) 2012-07-13
US20150073025A1 (en) 2015-03-12
PT2324126E (pt) 2014-06-02
CA2735578A1 (en) 2010-02-18
ME01898B (me) 2014-12-20
PE20151924A1 (es) 2016-01-13
AU2009282114B2 (en) 2016-04-07
EP2324126B1 (en) 2014-04-23
AU2018202373A1 (en) 2018-04-26

Similar Documents

Publication Publication Date Title
PE20110565A1 (es) Metodo de identificacion de factores de riesgo de la enfermedad
HN2008000346A (es) Secuencias de nucleotidos que codifican proteinas insecticidas
MX2024004195A (es) Biomarcadores de metabolitos para enfermedades asociadas con el sistema de activacion por contacto.
AR117199A2 (es) Evento das-40278-9 de aad-1, líneas transgénicas de maíz relacionadas, e identificación evento-específico de las mismas
CO6700873A2 (es) Planta y semilla de soja correspondiente al evento transgenico mon87712 y métodos para su detección.
MX2019008675A (es) Variantes de hidroxiesteroide 17-beta deshidrogenasa 13 (hsd17b13) y usos de estas.
BR112016007566A2 (pt) evento de milho transgênico mon87403 e métodos para a detecção do mesmo
WO2011071923A3 (en) Multi-sample indexing for multiplex genotyping
EA201600085A1 (ru) Набор для обнаружения соевого события syht0h2
PE20221408A1 (es) Nuevas proteinas inhibidoras de insectos
DOP2013000296A (es) Enfermedad tromboembólica
CL2022000131A1 (es) Método para detectar la presencia de un gen restaurador rf3 para el gen de la esterilidad masculina citoplasmática de tipo s del maíz. (divisional de solicitud 201601658)
BR112013025459A2 (pt) análise de alto rendimento de bordas de transgenes
BR112016006312A2 (pt) método e kit para determinar a presença ou ausência de staphylococcus aureus resistente à meticilina em uma amostra biológica
AR101779A2 (es) Secuencias de nucleótidos msca1 que afectan la fertilidad vegetal masculina y método para usar las mismas
MX2016016742A (es) Ceramidas y su uso en el diagnostico de enfermedad cardiovascular (ecv).
BR112015015500A2 (pt) método para o rastreamento completo de um conjunto de amostras biológicas contendo dna ou rna através da identificação do código de barras molecular durante o fluxo de trabalho de laboratório e kit para coleta de amostras biológicas de dna ou rna
CL2012002347A1 (es) Metodo in vitro para el diagnostico de la demencia con cuerpos de lewy (lbd), que comprende determinar en una muestra biológica de un individuo el genotipo de las siguientes alteraciones en el gen de la butirilcolinesterasa o de polimorfismos en desequilibrio de union de los mismos; kit para llevar a cabo dicho método; uso del kit para el diagnóstico de lbd.
BRPI1008936B8 (pt) método in vitro para detectar pré-disposição para ou diagnóstico e/ou prognóstico de fibrose hepática ou cirrose ocorrendo em um indivíduo humano
AR097489A1 (es) Marcadores de riesgo para cardiovasculopatías en pacientes con nefropatía crónica
AR113786A1 (es) Método para marcar secuencias de ácido nucleicos, composición y uso de la misma
AR101049A1 (es) Plantas de brassica que comprenden alelos mutantes de da1
CL2011003063A1 (es) Metodo de alto rendimiento para la deteccion de la presencia de dos o mas proteinas de interes con secuencias de aminoacidos conocidas en una muestra de planta, y procedimiento para mantener el genotipo de una variedad de la planta transgenica.
ES2351916B8 (es) Metodo de identificacion de celulas madre mesenquimales senescentes
MX2015017884A (es) Proceso para la determinación de la autenticidad de mieles mediante el establecimiento de su perfil proteico y desarrollo de un marcador molecular para mieles de distinto origen entomologico.

Legal Events

Date Code Title Description
FC Refusal